NEU-723

NEU-723 is a highly potent and selective, brain-penetrant small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2). It is being developed as a potential disease-modifying therapy for Parkinson’s disease, particularly targeting patients with LRRK2 gene variants, which are associated with both familial and sporadic forms of the disease. By inhibiting LRRK2 activity in the brain, NEU-723 aims to protect dopaminergic neurons from degeneration and slow or halt progression of Parkinson’s disease. The drug is also under preclinical investigation for systemic inflammatory diseases due to the role of LRRK2 in immune signaling. Neuron23 has paired development of NEU-723 with a companion diagnostic to identify patients most likely to benefit from therapy[1][3][4][5].